MétaCan
Menu
← Back to cohort
Record W4397041132 · doi:10.1681/asn.20233411s128c

Canagliflozin Pharmacokinetics at Steady State in Patients on Maintenance Hemodialysis

2023· article· en· W4397041132 on OpenAlexaff
Thomas A. Mavrakanas, Ari Gritsas, Efrosyne Tsirella, Norka Rios, Abhinav Sharma, Rita S. Suri

Bibliographic record

VenueJournal of the American Society of Nephrology · 2023
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsMcGill University Health Centre
Fundersnot available
KeywordsPharmacokineticsCanagliflozinHemodialysisMedicineIntensive care medicinePharmacologyUrologyInternal medicineEndocrinology

Abstract

fetched live from OpenAlex

Background: Sodium glucose co-transporter 2 (SGLT-2) inhibitors improve cardiovascular and kidney outcomes in patients with preserved renal function or with mild and moderate chronic kidney disease. However, they have not been studied in patients on maintenance hemodialysis (HD). Detailed study of SGLT-2 inhibitor pharmacokinetics in patients receiving HD is the first step to establishing their safety in this population. Methods: Patients with kidney failure on maintenance HD for at least 3 months were invited to participate. Those with type 1 diabetes mellitus, euglycemic ketoacidosis, or liver disease were excluded. All participants received 100 mg of canagliflozin once daily for nine days. Venous blood samples were collected immediately before (0) and 1, 1.5, 2, 3, 4, 6, 9, 12, and 24 hours after canagliflozin administration for pharmacokinetic analyses on day 8 (a mid-week non-dialysis day) and hourly during hemodialysis on day 9. Canagliflozin plasma levels were measured with liquid chromatography- mass spectrometry and compared to published estimates in healthy controls. Results: We enrolled 10 patients (59 ± 14 years old, 30% female, median dialysis duration 26 months). Canagliflozin levels reached steady state on day 4, based on a calculated half-life of 7.3 hours. Pharmacokinetic results on day 8 are shown in the Table. There were no significant differences in drug exposure, peak plasma levels, nor time to peak plasma levels between our patients and patients with preserved renal function. Canagliflozin levels were not modified by hemodialysis (p=0.39). Conclusions: Drug exposure with canagliflozin 100 mg daily is similar between patients receiving HD and individuals with preserved kidney function, and levels were not affected by HD. These results suggest canagliflozin does not accumulate in HD patients and trials of canagliflozin may be safely conducted in patients on HD to test its efficacy. Funding: Private Foundation Support Canagliflozin pharmacokinetics in hemodialysis - Parameter Hemodialysis Preserved renal function p-value AUC0-24 (ng.h/ml) 8267 ± 4265 6377 ± 1285 0.19 Cmin (ng/ml) 87 (57-201) - - tmax (hours) 2.1 (1.9-3.2) 2.0 (1.0-4.0) 0.18 Cmax (ng/ml) 1122 ± 537 943 ± 239 0.32 AUC0-24, drug exposure (area under the curve between 0 and 24h); Cmin, trough level; tmax, time to peak plasma concentration; Cmax, peak plasma concentration.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.003

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.270
Teacher spread0.256 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueJournal of the American Society of Nephrology→Same topicDiabetes Treatment and Management→French-language works237,207→